Determining the Activity of Imipenem/Relebactam Plus Aztreonam Against Constitutive Pseudomonas -Derived Cephalosporinase- and Metallo-β-Lactamase-Producing Pseudomonas aeruginosa in a Hollow Fiber Infection Model
Open Forum Infectious Diseases · 30.03.2026 · 13 (4)
DOI: 10.1093/ofid/ofag172 ↗Kurz gefasst
Fachartikel in der Zeitschrift Open Forum Infectious Diseases, online erschienen am 26.03.2026. Verfasst von J Nicholas O'Donnell und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy Practice, Albany College of Pharmacy and Health Sciences, Albany, New York, USA. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Merck & Co., Inc..
Abstract (Originalsprache)
Background
Few treatment options exist for serious infections caused by metallo-β-lactamase (MBL)-producing Pseudomonas aeruginosa. This study evaluated imipenem/relebactam (I/R) plus aztreonam (ATM) against Pseudomonas-derived cephalosporinase (PDC)- and MBL-producing P. aeruginosa in a hollow fiber infection model, with ceftazidime/avibactam (CZA) plus ATM as a comparator.
Methods
Two isogenic PDC- and MBL-producing P. aeruginosa isolates (MB10480: IMP-1; MB10620: VIM-1) were studied at a starting inoculum of ∼8 log10 CFU/mL over 96 hours. Humanized I/R exposures were evaluated alone and with extended-infusion ATM (1.5 g every 6 hours [q6h], 2 g q8h, and 2 g q6h), with CZA plus ATM (2 g q6h) as a comparator. Combinations were tested in triplicate, and ATM/relebactam or ATM/avibactam minimum inhibitory concentrations (MICs) were assessed at 96 hours.
Results
For both MB10480 (ATM/relebactam MIC: 8/4 mg/L) and MB10620 (4/4 mg/L), monotherapy arms mirrored the growth control. Both I/R plus ATM and CZA plus ATM produced early synergy (≥2 log10 CFU/mL reduction relative to the most active monotherapy) with >1 log10 CFU/mL killing relative to the starting inoculum at 24 hours, followed by regrowth, with bacteriostasis observed at 96 hours across regimens. However, bacterial counts at 96 hours were lowest with I/R plus ATM 2 g q6h. Two colony morphologies were recovered, and retested MICs were occasionally, but not consistently, elevated.
Conclusions
Both I/R plus ATM and CZA plus ATM showed early synergy against PDC- and MBL-producing P. aeruginosa, but regrowth occurred with all regimens. Higher-dose ATM with I/R provided more durable suppression, though persistence remained common, underscoring the need to better define dosing and mechanisms of regrowth.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmacy Practice, Albany College of Pharmacy and Health Sciences, Albany, New York, USA.
- Department of Infectious Diseases and Vaccines, Merck & Co., Inc., Rahway, New Jersey, USA.
ORCID-Profile: J Nicholas O'Donnell
Förderung
- Merck & Co., Inc.
Zitieren
APA
O'Donnell, J. N., Moolick, K. E., Nahorniak, A. I., Gifford, M. J., Young, K., & Lodise, T. P. (2026). Determining the Activity of Imipenem/Relebactam Plus Aztreonam Against Constitutive Pseudomonas -Derived Cephalosporinase- and Metallo-β-Lactamase-Producing Pseudomonas aeruginosa in a Hollow Fiber Infection Model. Open Forum Infectious Diseases, 13(4). https://doi.org/10.1093/ofid/ofag172
Vancouver
O'Donnell JN, Moolick KE, Nahorniak AI, Gifford MJ, Young K, Lodise TP. Determining the Activity of Imipenem/Relebactam Plus Aztreonam Against Constitutive Pseudomonas -Derived Cephalosporinase- and Metallo-β-Lactamase-Producing Pseudomonas aeruginosa in a Hollow Fiber Infection Model. Open Forum Infectious Diseases. 2026;13(4). doi:10.1093/ofid/ofag172
BibTeX
@article{ODonnell2026,
author = {O'Donnell, J Nicholas and Moolick, Kelly E and Nahorniak, Avery I and Gifford, Maxwell J and Young, Katherine and Lodise, Thomas P},
title = {Determining the Activity of Imipenem/Relebactam Plus Aztreonam Against Constitutive Pseudomonas -Derived Cephalosporinase- and Metallo-β-Lactamase-Producing Pseudomonas aeruginosa in a Hollow Fiber Infection Model},
journal = {Open Forum Infectious Diseases},
year = {2026},
volume = {13},
number = {4},
doi = {10.1093/ofid/ofag172}
}
EUVIMED